(+)-Episesamin exerts anti-neoplastic effects in human hepatocellular carcinoma cell lines via suppression of nuclear factor-kappa B and inhibition of MMP-9 Christian FreiseWolfram Trowitzsch-KienastRajan Somasundaram PRECLINICAL STUDIES 03 November 2011 Pages: 2087 - 2095
Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patients Maria Cristina VillarroelKeith W. PratzMichelle A. Rudek PRECLINICAL STUDIES 17 November 2011 Pages: 2096 - 2102
Identification of cyclohexanone derivatives that act as catalytic inhibitors of topoisomerase I: effects on tamoxifen-resistant MCF-7 cancer cells Euphemia LeungGordon W. RewcastleBruce C. Baguley PRECLINICAL STUDIES Open access 22 November 2011 Pages: 2103 - 2112
MK-4827, a PARP-1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation Li WangKathy A. MasonLuka Milas PRECLINICAL STUDIES 30 November 2011 Pages: 2113 - 2120
Thymoquinone reduces migration and invasion of human glioblastoma cells associated with FAK, MMP-2 and MMP-9 down-regulation Kaouther Kolli-BouhafsAbdelaziz BoukhariPhilippe Rondé PRECLINICAL STUDIES 15 December 2011 Pages: 2121 - 2131
Pretargeting of necrotic tumors with biotinylated hypericin using 123I-labeled avidin: evaluation of a two-step strategy Thierry MarysaelMatthias BauwensPeter de Witte PRECLINICAL STUDIES 21 December 2011 Pages: 2132 - 2140
Using the neurotransmitter serotonin to target imaging agents to glioblastoma cells Alexander SturzuSumbla SheikhStefan Heckl PRECLINICAL STUDIES 28 January 2012 Pages: 2141 - 2147
The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines Hyun-Jin NamHwang-Phill KimYung-Jue Bang PRECLINICAL STUDIES 25 December 2011 Pages: 2148 - 2160
Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models Sharon L. LongoDavid J. PadalinoDawn E. Post PRECLINICAL STUDIES 29 December 2011 Pages: 2161 - 2172
Assessment of the novel tubulin-binding agent EHT 6706 in combination with ionizing radiation or chemotherapy Céline ClémensonCyrus ChargariEric Deutsch PRECLINICAL STUDIES 14 January 2012 Pages: 2173 - 2186
Quinones and halogenated monoterpenes of algal origin show anti-proliferative effects against breast cancer cells in vitro Jo-Anne de la MareJessica C. LawsonGregory L. Blatch PRECLINICAL STUDIES 17 January 2012 Pages: 2187 - 2200
Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models David A. ProiaJim SangYumiko Wada PRECLINICAL STUDIES Open access 10 January 2012 Pages: 2201 - 2209
Ent-11α-hydroxy-15-oxo-kaur-16-en-19-oic-acid inhibits hepatocellular carcinoma in vitro and in vivo via stabilizing IkBα George G. ChenJackie LeungPaul B. S. Lai PRECLINICAL STUDIES 07 January 2012 Pages: 2210 - 2218
Combination of ATP-competitive mammalian target of rapamycin inhibitors with standard chemotherapy for colorectal cancer Chloe E. AtreyaGregory S. DuckerKevan M. Shokat OriginalPaper 24 January 2012 Pages: 2219 - 2225
Blood glutamate scavengers prolong the survival of rats and mice with brain-implanted gliomas Angela RubanTamara BerkutzkiVivian I. Teichberg PRECLINICAL STUDIES Open access 02 February 2012 Pages: 2226 - 2235
Screening of drugs to counteract human papillomavirus 16 E6 repression of E-cadherin expression Zarina J. D’CostaCheng-Mee LeongMerilyn H. Hibma PRECLINICAL STUDIES 23 February 2012 Pages: 2236 - 2251
Proteasome inhibitor MG132 induces selective apoptosis in glioblastoma cells through inhibition of PI3K/Akt and NFkappaB pathways, mitochondrial dysfunction, and activation of p38-JNK1/2 signaling Alfeu Zanotto-FilhoElizandra BraganholJosé Cláudio Fonseca Moreira PRECLINICAL STUDIES 28 February 2012 Pages: 2252 - 2262
Screening candidate anticancer drugs for brain tumor chemotherapy: Pharmacokinetic-driven approach for a series of (E)-N-(substituted aryl)-3-(substituted phenyl)propenamide analogues Hua LvFan WangJames M. Gallo PRECLINICAL STUDIES 01 March 2012 Pages: 2263 - 2273
Evaluation of deoxyhypusine synthase inhibitors targeting BCR-ABL positive leukemias Patrick ZieglerTuhama ChahoudTim H. Brümmendorf PRECLINICAL STUDIES 14 March 2012 Pages: 2274 - 2283
Anti-leukemic effect of 2-pyrone derivatives via MAPK and PI3 kinase pathways Jin Sun YoonYoung Woong WonYoung Yiul Lee PRECLINICAL STUDIES 19 April 2012 Pages: 2284 - 2293
Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma Jason KonnerRachel N. GrishamCarol Aghajanian PHASE I STUDIES 10 November 2011 Pages: 2294 - 2302
Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination Michael MillwardTimothy PriceMatthew A. Spear PHASE I STUDIES 12 November 2011 Pages: 2303 - 2317
Phase I dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumors C. MassardR. SalazarJ. C. Soria PHASE I STUDIES 04 January 2012 Pages: 2318 - 2326
First clinical pharmacokinetic dose-escalation study of sagopilone, a novel, fully synthetic epothilone, in Japanese patients with refractory solid tumors Kazuhiro ArakiKoichi KitagawaYasutsuna Sasaki PHASE I STUDIES 04 December 2011 Pages: 2327 - 2333
Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies Glen J. WeissManuel HidalgoDaniel D. Von Hoff PHASE I STUDIES 09 December 2011 Pages: 2334 - 2343
A phase I study of temozolomide and everolimus (RAD001) in patients with newly diagnosed and progressive glioblastoma either receiving or not receiving enzyme-inducing anticonvulsants: an NCIC CTG study Warren P. MasonMary MacNeilElizabeth Eisenhauer PHASE I STUDIES 09 December 2011 Pages: 2344 - 2351
Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors Toshiaki TakahashiNarikazu BokuNobuyuki Yamamoto PHASE I STUDIES Open access 17 January 2012 Pages: 2352 - 2363
Phase I trial of ixabepilone administered as three oral doses each separated by 6 hours every 3 weeks in patients with advanced solid tumors Pamela L. KunzAiwu R. HeJohn L. Marshall PHASE I STUDIES 14 February 2012 Pages: 2364 - 2370
A phase II trial of Erlotinib in combination with gemcitabine and cisplatin in advanced pancreatic cancer In Gyu HwangJoung-Soon JangJung Hun Kang PHASE II STUDIES 03 February 2012 Pages: 2371 - 2376
Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group S. H. ParkM. H. RyuY. K. Kang PHASE II STUDIES 25 January 2012 Pages: 2377 - 2383
Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease Thomas YauHilda WongRonnie T. Poon PHASE II STUDIES Open access 09 March 2012 Pages: 2384 - 2390
Integrated preclinical and clinical development of S-trans, trans-farnesylthiosalicylic acid (FTS, Salirasib) in pancreatic cancer Daniel LaheruPreeti ShahManuel Hidalgo PHASE II STUDIES 01 May 2012 Pages: 2391 - 2399
Renal dysfunction in a renal transplant patient treated concurrently with cyclosporine and imatinib Karen E. MulderMerrill J. EgorinMichael B. Sawyer SHORT REPORT 25 November 2011 Pages: 2400 - 2402
SOCS1 is significantly up-regulated in Nutlin-3-treated p53wild-type B chronic lymphocytic leukemia (B-CLL) samples and shows an inverse correlation with miR-155 Maria Grazia di IasioAlessia NorcioGiorgio Zauli SHORT REPORT 13 January 2012 Pages: 2403 - 2406
Severe meningo-radiculo-nevritis associated with ipilimumab Flavie BompaireChristine MateusDamien Ricard SHORT REPORT 11 January 2012 Pages: 2407 - 2410
Aurora kinase inhibitors: Progress towards the clinic Madhu KollareddyDaniella ZhelevaMarian Hajduch REVIEW Open access 18 February 2012 Pages: 2411 - 2432
Clinical development of insulin-like growth factor receptor—1 (IGF-1R) inhibitors: At the crossroad? Andrea GombosOtto Metzger-FilhoAhmad Awada-Hussein REVIEW Open access 14 March 2012 Pages: 2433 - 2442
Predictive factors for response to treatment in patients with advanced renal cell carcinoma Carolina Muriel LópezEmilio EstebanPablo Martínez-Camblor REVIEW 27 May 2012 Pages: 2443 - 2449
Erratum to: Phase I clinical, pharmacokinetic, and pharmacodynamic study of KOS-862 (Epothilone D) in patients with advanced solid tumors and lymphoma Jason KonnerRachel N. GrishamCarol Aghajanian Erratum 03 January 2012 Pages: 2450 - 2450
Erratum to: Assessment of the novel tubulin-binding agent EHT 6706 in combination with ionizing radiation or chemotherapy Céline ClémensonCyrus ChargariEric Deutsch Erratum 06 March 2012 Pages: 2451 - 2453